Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Itraconazole on PF-06648671 PK in Healthy Adults
NCT02883114Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06648671 in Alzheimer's disease (AD), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 5 more. Started Sep 2016; status: completed.
02
Drugs
PF-06648671
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02883114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883114.